iTolerance, Inc. Awarded Industry Discovery and Development Partnership with JDRF for Advanced Pre-Clinical Development of iTOL-100 and iTOL-101 for the Treatment of Type 1 Diabetes

Company advancing development of lead program, iTOL-101, as a potential breakthrough in curing Type 1 Diabetes with the potential to eliminate the need for chronic life-long immunosuppressionThe up to

Related Keywords

United States ,Miami ,Florida ,Anthony Japour ,Jenene Thomas ,Kostenloser Wertpapierhandel ,Esther Latres ,Instagram ,Facebook ,Good Laboratory Practice ,Tolerance Inc ,Development Partnership ,Industry Discovery ,Chief Executive Officer ,Fas Ligand ,Private Securities Litigation Reform Act ,Itolerance ,Warded ,Industry ,Discovery ,Development ,Partnership ,Drf ,Dvanced ,Linical ,Tol ,Treatment ,Type ,Diabetes ,